Prohibiting the sale of dextromethorphan to minors
Impact
If enacted, HB 2226 will amend Chapter 94C of the General Laws of Massachusetts, creating a new section that outlines clear restrictions on the sale and purchase of products containing dextromethorphan. This change will enforce strict age verification procedures for retailers and establish penalties for both retailers and underage buyers. The legislation also includes a stipulation that it preempts any local ordinances that may impose additional regulations on the sale of dextromethorphan, thereby centralizing authority at the state level.
Summary
House Bill 2226 seeks to prohibit the sale of dextromethorphan, a common ingredient in many over-the-counter cough suppressants, to individuals under the age of 18. The bill aims to address growing concerns about the misuse of the substance by minors and the potential health risks associated with its unsupervised consumption. Under this legislation, retailers would be required to verify the age of purchasers through valid photo identification and would face penalties for non-compliance with the regulations outlined in the bill.
Contention
While the intent of HB 2226 is to promote public health and safety, there may be points of contention regarding its enforcement and the responsibilities placed on retailers. Critics might argue that the bill does not address underlying issues of drug misuse among minors and may overburden retailers with compliance demands. Additionally, concerns may arise regarding the fairness of penalizing individuals under the age of 18 for attempting to purchase dextromethorphan, which could prompt discussions about alternative educational or preventative measures.
Prohibiting the transfer of hemp-derived cannabinoid products to any person under the age of 21, establishing packaging and labeling requirements for such products and amending the definition of industrial hemp and hemp products.